Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib Article

cited authors

  • Lara, Primo N., Jr.; Longmate, Jeff; Mack, Philip C.; Kelly, Karen; Socinski, Mark A.; Salgia, Ravi; Gitlitz, Barbara; Li, Tianhong; Koczywas, Mariana; Reckamp, Karen L.; Gandara, David R.

authors

Publication Date

  • October 1, 2015

webpage

published in

category

start page

  • 4321

end page

  • 4326

volume

  • 21

issue

  • 19